A number of solid tumors are treated with radiation therapy (RT) as a curative modality. At the same time, for certain types of cancers the applicable doses of RT are not high enough to result in a successful eradication of cancer cells. This is often caused by limited pharmacological tools and strategies to selectively sensitize tumors to RT while simultaneously sparing normal tissues from RT. We present an outline of a novel strategy for RT sensitization of solid tumors utilizing Jak inhibitors. Here, recently published pre-clinical data are reviewed which demonstrate the promising role of Jak inhibition in sensitization of tumors to RT. A wide number of currently approved Jak inhibitors for non-malignant conditions are summarized including Jak inhibitors currently in clinical development. Finally, intersection between Jak/Stat and the levels of serum cytokines are presented and discussed as they relate to susceptibility to RT.

许多实体瘤采用放射疗法 (RT) 作为治愈方式进行治疗。同时，对于某些类型的癌症，适用的放疗剂量不足以成功根除癌细胞。这通常是由于有限的药理学工具和策略导致肿瘤选择性地对放疗敏感，同时使正常组织免受放疗。我们概述了利用 Jak 抑制剂对实体瘤进行 RT 致敏的新策略。在这里，回顾了最近发表的临床前数据，这些数据证明了 Jak 抑制在肿瘤对 RT 敏感方面的有希望的作用。总结了目前批准用于非恶性疾病的大量 Jak 抑制剂，包括目前处于临床开发阶段的 Jak 抑制剂。最后，